HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.